Is the Testis a Chemo-Privileged Site? Is There a Blood-Testis Barrier?

Reviews in Urology

Dhiren S Dave¹  Jacob Rajfer¹  John T Leppert¹ 

[1] Division of Urology, Harbor-UCLA Medical Center, Torrance, CA

关键词: Testicular cancer;    Blood-testis barrier;    Orchiectomy;    Chemotherapy;   

DOI  :  

学科分类：基础医学

来源: MedReviews, LLC

【 摘 要 】

The incidence of testicular cancer, primarily seminoma, has been increasing in many countries, including the United States. The testis is often the site of residual cancer after adequate treatment with systemic chemotherapy. The blood-testis barrier is commonly cited as the explanation for residual tumor within the gonad after chemotherapy and as the indication for delayed orchiectomy. Conversely, complete eradication of viable tumor from the primary site is common and argues against the testis as a “tumor sanctuary.” Residual tumor is also demonstrated within metastatic foci, and the disparity between the histopathologic response of the primary tumor and metastatic sites may be best explained by tumor heterogeneity and multiple tumor clones. Regardless of the scientific and academic arguments, delayed radical orchiectomy remains an important part of treatment for patients undergoing primary chemotherapy.

【 授权许可】

Unknown